FDA peptide compounding status and safety signals

Clinical Question

What is the current FDA regulatory status for commonly utilized therapeutic peptides, and what emerging safety signals have been identified through clinical trials and postmarketing surveillance?

Evidence Snapshot

• Regulatory Status: Multiple peptides including BPC-157, TB-500, and CJC-1295 are currently listed under FDA Category 2 (503A/503B), identifying them as substances with significant safety risks or lack of safety data.
• FDA Approved Status: Semaglutide, Tirzepatide, and Tesamorelin have FDA approval for specific indications; others like BPC-157, Selank, and Semax do not have FDA approval.
• Warning Letters: Warning letters were issued in 2020 to Tailor Made Compounding and Predator Nutrition regarding various peptide products.
• Safety Signals (Semaglutide): Strong signals for nausea, vomiting, and delayed gastric emptying; emerging signals for pulmonary aspiration and NAION.
• Clinical Outcomes: Phase III trials (STEP 1, SELECT, SURMOUNT-1) demonstrate significant therapeutic efficacy for approved weight loss and CV indications.

What the Research Shows

As of March 2026, the regulatory landscape for peptide therapies is defined by significant FDA scrutiny of compounding materials. Peptides such as BPC-157, TB-500, AOD-9604, CJC-1295, Ipamorelin, Selank, and Semax are not FDA-approved. The FDA has categorized these as Category 2 bulk substances under sections 503A and 503B, citing safety risks, immunogenicity concerns, and a lack of human exposure data. Specifically, for CJC-1295, the FDA noted concerns regarding increased heart rate. Thymosin Alpha-1, while approved as Zadaxin in over 35 countries, lacks FDA approval and remains a substance of concern under interim policy.

In clinical outcomes research, Thymosin Alpha-1 failed to show mortality reduction in a Phase III sepsis trial (NCT02867267). Conversely, approved peptides have demonstrated substantial clinical efficacy: Semaglutide achieved 14.9% weight loss in the STEP 1 trial and a 20% MACE reduction in the SELECT trial. Tirzepatide demonstrated 22.5% weight loss in SURMOUNT-1, proving superior to semaglutide in head-to-head Phase IIIb trials (SURMOUNT-5). Retatrutide showed 24.2% weight loss at 12mg in Phase II trials, with Phase III (TRIUMPH-3) currently recruiting.

Safety surveillance through FAERS for semaglutide indicates a total of 187,757 GLP-1 RA reports through 2023. While gastrointestinal events like nausea and vomiting are strong, labeled signals, there are emerging signals for pulmonary aspiration (added to the Ozempic label in 2025) and Nonarteritic Anterior Ischemic Optic Neuropathy (NAION), which was under EMA review as of January 2025 following 96 reported cases.

Mechanism

The provided data does not contain mechanistic descriptions for the regulatory classifications or the primary therapeutic effects of the listed peptides, other than noting that certain safety signals, such as acute kidney injury, often occur in the context of gastrointestinal-related dehydration, and pulmonary aspiration is associated with delayed gastric emptying.

Limitations of the Evidence

The primary limitation for many non-approved peptides, such as TB-500 and BPC-157, is the total absence of human exposure data or formal safety studies. Regulatory notes specifically mention "immunogenicity concerns" and "lack of safety data" as reasons for Category 2 placement. Furthermore, while Russia has approved Selank and Semax (specifically for stroke), these data have not been validated by US regulatory authorities. Emerging signals such as NAION and suicidal ideation are currently under evaluation or formal review; data currently available for the latter do not support a risk higher than background levels.

Clinical Takeaway

Physicians should be aware that the FDA has classified several bulk peptides as Category 2 substances due to immunogenicity and safety risks, making them ineligible for routine compounding. While approved GLP-1 and GIP/GLP-1 agonists show strong clinical efficacy in Phase III trials, they are associated with increasing evidence of adverse events including ileus, gallbladder issues, and emerging risks related to pulmonary aspiration during anesthesia.

Sources

1. FDA 503A/503B Regulatory Status Records (As of March 2026).
2. FAERS Safety Signal Database (2023-2025 updates).
3. Clinical Trial Records: NCT03548935 (STEP 1), NCT03574597 (SELECT), NCT04184622 (SURMOUNT-1), NCT05024032 (SURMOUNT-5), NCT04881706 (Retatrutide), NCT02867267 (Sepsis).
4. FDA Warning Letters: Tailor Made Compounding (2020), Predator Nutrition (2020).

This content is sourced exclusively from TruthTides clinical reference data and does not constitute medical advice.